BSEM
BioStem Technologies, Inc.
Biotechnology · Healthcare · United States
1.29
close · 2026-10-29
value
98
cheaper than peers98
quality
32
stronger fundamentals32
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 4.45× | 99 |
| price to sales | 1.52× | 93 |
| price to book | 0.83× | 89 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 10.3% | 60 |
| operating margin | -144.8% | 50 |
| return on equity | -48.6% | 50 |
| revenue growth | -61.6% | 14 |
4 of 4 measures available
Facts
| market cap | $24M |
| free cash flow | $19.2M |
| employees | 73 |
| first trade | 2015-03-17 |
| next earnings | 2026-11-12 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2024 | 2023 | 2022 | 2021 |
| diluted eps | 1.47 | -0.62 | -0.63 | -0.12 |
| free cash flow | $24.1M | -$3.7M | -$165,909 | -$152,287 |
| net income | $31.9M | -$8.5M | -$7.2M | -$1.4M |
| revenue | $301.8M | $16.7M | $6.9M | $4.3M |
| unusual items | not reported | $0 | -$2.1M | $689,361 |